



Press Release / Press Release

**GENFIT ANNOUNCES SOLID FINANCIAL RESULTS FOR 2005
AND AN AMBITIOUS OUTLOOK FOR 2006**

***Sixth profitable year in succession combined with record revenues
and further investment in R&D***

Lille (France), Cambridge (Massachusetts), 4 July 2006 – GENFIT, the biopharmaceutical company engaged in the discovery and development of medical candidates in the areas of cardiovascular, inflammatory and metabolic diseases, today reported its annual results for 2005.

- Revenues increased to € 12.9 million (\$16.5 million) compared with € 12.2 million (\$15.6 million) in 2004
- Cumulative R&D investment, since the creation of the company in 1999, reached nearly € 60 million (\$76.8 million) at the end of 2005
- Net profit for the sixth consecutive year of € 1.4 million (\$1.8 million), identical to the results reported for the previous year
- Cash and cash equivalents amounting to € 17.9 million (\$22.9 million) at the end of 2005

Key Company Events in 2005 :

Signature of a new agreement with Pierre Fabre. GENFIT and the Pierre Fabre pharma group reinforced their collaboration, initiated in October 2001. This agreement confirms Genfit's capacity for identifying new molecules which have a simultaneous action on several conditions such as diabetes and lipid disorders.

Strong advancement in product pipeline. Two of GENFIT's leading molecules entered into advanced development phases after the successful completion of proof of concept trials (pre-clinical studies for GFT505 and extremely encouraging Phase I results for GFT14.) Progress across additional programs at earlier stages of development also validated the enormous potential for the multimodal approach adopted by the company, which allows for a simultaneous response to various aspects of cardiometabolic risk.

Expansion of intellectual property framework. In 2005, GENFIT filed 42 new patents, bringing the total number of proprietary patents filed by the company to 158. These patents protect new chemical entities identified by the company, which are due to generate a significant number of future targets to reinforce the pipeline.

International recognition. GENFIT joined other prestigious establishments recognised by the International Institute of Promotion and Prestige, based in Geneva, which awarded the company with the “Prize of Merit for Development in Research” in November 2005.

Florence SEJOURNE, Vice President, COO and Member of the Board of Directors commented :

“2005 was a year of unprecedented success for GENFIT. Each of our 15 research programs yielded positive scientific results. In terms of company growth, 2005 witnessed optimal structuralization across the board in order to explore additional innovative research leads, focus on new promising therapeutic axes and widen our international network of collaborations.”

Jean-François MOUNEY, Chairman and CEO, added, : *“Strengthened by this solid position, GENFIT intends to accelerate its development and targeted investments in order to build a rich and diverse portfolio of medical candidates. 2006 will see strong progress, with the achievement of important milestones for our proprietary molecules. In order to capitalize on market opportunities, we are establishing a sizeable financial structure in order to fuel further investment and growth in the years to come and ensure our worldwide leadership in its core therapeutic areas. “*

About GENFIT

The emerging biopharmaceutical company, GENFIT studies gene deregulation, which is at the origin of some of the most wide-spread diseases. The GENFIT group identifies new therapeutic targets and develops drug candidates. The company's most advanced programs, conducted internally or in partnership with industry leaders such as SANOFI - AVENTIS, PIERRE FABRE, FOURNIER, MERCK AG, KOWA and SERVIER, concentrate on the treatment of key metabolic and inflammatory disorders. GENFIT's initial proprietary medicines concentrate on global cardiovascular risk by treating several pathologies, such as atherosclerosis, diabetes and obesity, simultaneously with a single molecule. Founded and managed by Professeur Jean-Charles FRUCHART and Mr. Jean-François MOUNEY, the company is headquartered in Lille with facilities in Cambridge (USA). The company currently employs 120 people. (www.genfit.com)

Contacts

GENFIT :

Jean-François MOUNEY, Chairman and CEO

Kate PORTER, Corporate Communications Manager

Phone : +33 (0) 3 20 16 40 11

Phone : +33 (0) 3 20 16 40 79

MILESTONES – Press Relations :

Bruno ARABIAN

Phone : +33 (0) 1 70 08 04 13

Phone : +33 (0) 6 87 88 47 26